Literature DB >> 27193063

Time course and predictors of use of erectile dysfunction treatment in a Veterans Affairs medical center.

R I Clavijo1, T Daskivich1, L Kwan1, J Bassett2, T Keller3, C Bennett1,3.   

Abstract

The objective of this study was to define the pattern and time course of use of ED treatments in a Veterans Affairs (VA) medical center and to identify clinical or demographic variables that are associated with the use of second- or third-line ED treatments. We identified 702 men treated for ED at the Greater Los Angeles Veterans Affairs between 2007 and 2013. We extracted demographics, Charlson co-morbidity score, pertinent surgical/medication history as well as use of ED treatments from medical records. On multivariate analysis, age over 65 (OR 1.83, 95% CI: 1.31-2.56) and Charlson co-morbidity score of 1 (OR 1.77, 95% CI: 1.13-2.77) and 2+ (OR 2.07, 95% CI: 1.28-3.36) were significantly associated with use of medicated urethral suppositories for erection (MUSE)/intracorporal injections (ICI) compared with PDE5i/erection devices. Across all men who used second- or third-line treatments, median time until receiving MUSE was 0.6 years and median time until receiving ICI/implant was 2 years. We conclude that men who will ultimately use more invasive ED treatments, such as men with more co-morbidities, tend to have a prolonged treatment course. This information may be incorporated into a shared decision-making model for more efficient treatment of ED.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27193063     DOI: 10.1038/ijir.2016.20

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  10 in total

1.  Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy.

Authors:  J Baniel; S Israilov; E Segenreich; P M Livne
Journal:  BJU Int       Date:  2001-07       Impact factor: 5.588

2.  Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database.

Authors:  Raanan Tal; Lindsay M Jacks; Elena Elkin; John P Mulhall
Journal:  J Sex Med       Date:  2011-03-22       Impact factor: 3.802

3.  Modern utilization of penile prosthesis surgery: a national claim registry analysis.

Authors:  R L Segal; S B Camper; A L Burnett
Journal:  Int J Impot Res       Date:  2014-05-15       Impact factor: 2.896

4.  Men with diabetes may require more aggressive treatment for erectile dysfunction.

Authors:  T J Walsh; J M Hotaling; A Smith; C Saigal; H Wessells
Journal:  Int J Impot Res       Date:  2013-12-19       Impact factor: 2.896

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Health-related quality of life in men with erectile dysfunction.

Authors:  M S Litwin; R J Nied; N Dhanani
Journal:  J Gen Intern Med       Date:  1998-03       Impact factor: 5.128

Review 7.  Erectile dysfunction.

Authors:  Rany Shamloul; Hussein Ghanem
Journal:  Lancet       Date:  2012-10-05       Impact factor: 79.321

Review 8.  PDE5 inhibitors: considerations for preference and long-term adherence.

Authors:  W B Smith; I R McCaslin; A Gokce; S H Mandava; L Trost; W J Hellstrom
Journal:  Int J Clin Pract       Date:  2013-08       Impact factor: 2.503

9.  Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction.

Authors:  Vinay Prabhu; Joseph P Alukal; Juliana Laze; Danil V Makarov; Herbert Lepor
Journal:  J Urol       Date:  2012-11-20       Impact factor: 7.450

10.  Contemporary patient satisfaction rates for three-piece inflatable penile prostheses.

Authors:  Raymond M Bernal; Gerard D Henry
Journal:  Adv Urol       Date:  2012-07-26
  10 in total
  1 in total

1.  An increased prevalence of medical co-morbidities may underscore future growth in the numbers of men requiring penile prostheses.

Authors:  Jason Akerman; Jason R Kovac
Journal:  Transl Androl Urol       Date:  2017-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.